- KSQ-004EX, a dual-edit eTIL investigational therapy in which both the Regnase-1 and SOCS1 genes are inactivated by CRISPR/Cas9 gene editing, is also manufactured using our ExPRESS process.
- Using our in vivo CRISPR2® screening approach, we identified Regnase-1 and SOCS1 as the genome’s top dual-edit combination driving best-in-biology anti-tumor potential.
- The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase 1/2 clinical study of KSQ-004EX.
